IBDEI0WD ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15985,0)
 ;;=414.3^^92^930^17
 ;;^UTILITY(U,$J,358.3,15985,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15985,1,4,0)
 ;;=4^414.3
 ;;^UTILITY(U,$J,358.3,15985,1,5,0)
 ;;=5^CAD d/t Lipid Rich Plaque
 ;;^UTILITY(U,$J,358.3,15985,2)
 ;;=^336601
 ;;^UTILITY(U,$J,358.3,15986,0)
 ;;=414.4^^92^930^16
 ;;^UTILITY(U,$J,358.3,15986,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15986,1,4,0)
 ;;=4^414.4
 ;;^UTILITY(U,$J,358.3,15986,1,5,0)
 ;;=5^CAD d/t Calc Coronary Lesion
 ;;^UTILITY(U,$J,358.3,15986,2)
 ;;=^340518
 ;;^UTILITY(U,$J,358.3,15987,0)
 ;;=425.11^^92^930^60
 ;;^UTILITY(U,$J,358.3,15987,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15987,1,4,0)
 ;;=4^425.11
 ;;^UTILITY(U,$J,358.3,15987,1,5,0)
 ;;=5^Hypertrophic Subaortic Stenosis
 ;;^UTILITY(U,$J,358.3,15987,2)
 ;;=^340520
 ;;^UTILITY(U,$J,358.3,15988,0)
 ;;=425.18^^92^930^59
 ;;^UTILITY(U,$J,358.3,15988,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15988,1,4,0)
 ;;=4^425.18
 ;;^UTILITY(U,$J,358.3,15988,1,5,0)
 ;;=5^Hypertrophic Cardiomyopathy
 ;;^UTILITY(U,$J,358.3,15988,2)
 ;;=^340521
 ;;^UTILITY(U,$J,358.3,15989,0)
 ;;=V12.55^^92^930^54
 ;;^UTILITY(U,$J,358.3,15989,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15989,1,4,0)
 ;;=4^V12.55
 ;;^UTILITY(U,$J,358.3,15989,1,5,0)
 ;;=5^Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,15989,2)
 ;;=^340615
 ;;^UTILITY(U,$J,358.3,15990,0)
 ;;=454.9^^92^930^84
 ;;^UTILITY(U,$J,358.3,15990,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15990,1,4,0)
 ;;=4^454.9
 ;;^UTILITY(U,$J,358.3,15990,1,5,0)
 ;;=5^Varicose Veins
 ;;^UTILITY(U,$J,358.3,15990,2)
 ;;=^328758
 ;;^UTILITY(U,$J,358.3,15991,0)
 ;;=271.3^^92^931^11
 ;;^UTILITY(U,$J,358.3,15991,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15991,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,15991,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,15991,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,15992,0)
 ;;=611.1^^92^931^16
 ;;^UTILITY(U,$J,358.3,15992,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15992,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,15992,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,15992,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,15993,0)
 ;;=704.1^^92^931^17
 ;;^UTILITY(U,$J,358.3,15993,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15993,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,15993,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,15993,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,15994,0)
 ;;=251.2^^92^931^30
 ;;^UTILITY(U,$J,358.3,15994,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15994,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,15994,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,15994,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,15995,0)
 ;;=253.2^^92^931^34
 ;;^UTILITY(U,$J,358.3,15995,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15995,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,15995,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,15995,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,15996,0)
 ;;=733.00^^92^931^43
 ;;^UTILITY(U,$J,358.3,15996,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15996,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,15996,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,15996,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,15997,0)
 ;;=278.00^^92^931^40
 ;;^UTILITY(U,$J,358.3,15997,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15997,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,15997,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,15997,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,15998,0)
 ;;=278.01^^92^931^39
 ;;^UTILITY(U,$J,358.3,15998,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15998,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,15998,1,5,0)
 ;;=5^Morbid Obesity
